You just read:

New Updated Data Will be Presented From Oncopeptides' Pivotal Phase 2 HORIZON Study in Patients With Extra Medullary Disease (EMD) on September 15th

News provided by

Oncopeptides AB

30 Aug, 2019, 07:26 BST